Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB in Femoropopliteal Arteries

CompletedOBSERVATIONAL
Enrollment

249

Participants

Timeline

Start Date

August 20, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2020

Conditions
Peripheral Artery Disease
Trial Locations (16)

431-796

Hallym University Sacred Heart Hospital, Anyang-si

Unknown

Soonchunjyang University Hospital, Bucheon-si

Kangbuk Samsung Hospital, Seoul

Busan Veterans Hospital, Busan

Inje University Busan Park Hospital, Busan

412-270

Myongji Hospital, Goyang-si

700-712

Keimyung University Dongsan Medical Center, Daegu

705-703

YeungNam University Medical Center, Daegu

301-721

Chungnam National University Hospital, Daejeon

501-757

Chonnam National University Hospital, Gwangju

400-711

Inha University Hospital, Incheon

110-799

Seoul National University Hospital, Seoul

137-040

Seoul St. Mary's Hospital, Seoul

138-736

Asan Medical Center, Seoul

143-729

Konkuk University Hospital, Seoul

443-380

Ajou University Hospital, Suwon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02717104 - Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB in Femoropopliteal Arteries | Biotech Hunter | Biotech Hunter